A Tumultuous Journey of Metastatic Pancreatic Neuroendocrine Tumor with Carcinoid Syndrome
DOI:
https://doi.org/10.15605/jafes.040.01.04Keywords:
pancreatic neuroendocrine tumor, metastatic, octreotide refractory, peptide receptor radionuclide therapy, norepinephrineAbstract
A 25-year-old woman presented with metastatic pancreatic neuroendocrine tumor with carcinoid syndrome. She was refractory to octreotide and did not respond well to chemotherapy. Although surgical debulking remains the primary approach for managing these tumours, it entails inherent risks, including potentially exacerbating carcinoid syndrome. We strategically delivered the one Peptide Receptor Radionuclide Therapy cycle before tumor debulking, a decision that yielded a remarkable response, stabilizing her condition.
Downloads
References
1. Hofland J, Falconi M, Christ E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. https://pubmed.ncbi.nlm.nih.gov/37578384 https://doi.org/10.1111/jne.13318
2. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60. https://pubmed.ncbi.nlm.nih.gov/32272208 https://doi.org/10.1016/j.annonc.2020.03.304
3. Bertani E, Fazio N, Radice D, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases. Ann Surg Oncol. 2016;23(Suppl 5):981-9. https://pubmed.ncbi.nlm.nih.gov/27613553 https://doi.org/10.1245/s10434-016-5550-3
4. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):645-51. https://pubmed.ncbi.nlm.nih.gov/18847650 https://doi.org/10.1016/j.surg.2008.06.008
5. Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38(9):1669-74. https://pubmed.ncbi.nlm.nih.gov/21559978 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151371 https://doi.org/10.1007/s00259-011-1835-8
6. Partelli S, Bertani E, Bartolomei M, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163(4):761-7. https://pubmed.ncbi.nlm.nih.gov/29284590 https://doi.org/10.1016/j.surg.2017.11.007
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Somdatta Giri, Sadishkumar Kamalanathan, Kalayarasan Raja, Nandini Pandit, Jayaprakash Sahoo, Dukhabandhu Naik
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
